AxoGen Insiders Sold US$639k Of Shares Suggesting Hesitancy
A number of AxoGen, Inc. (NASDAQ:AXGN) insiders sold their shares in the last year, which may have raised concerns among investors. Knowing whether insiders are buying is usually more helpful when
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
Express News | AxoGen Inc : Raymond James Initiates Coverage With Outperform Rating; Target Price $13
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an
Raymond James Initiates AxoGen(AXGN.US) With Buy Rating, Announces Target Price $13
Raymond James analyst Jayson Bedford initiates coverage on $AxoGen(AXGN.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 64.2% and
Axogen Initiated at Outperform by Raymond James
Axogen Initiated at Outperform by Raymond James
Raymond James Initiates Coverage On Axogen With Outperform Rating, Announces Price Target of $13
Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price Target of $13.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
Axogen Launches New Product to Aid Nerve Healing: Avive+ Soft Tissue Matrix
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matr
Express News | Canaccord Genuity Reiterates Buy on Axogen, Maintains $15 Price Target
Axogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 114.13% Canaccord Genuity $15 → $15 Reiterates Buy → Buy 01/19/2024 71.31% Cantor Fitzgerald →
AxoGen, Inc.'s (NASDAQ:AXGN) Shares Leap 27% Yet They're Still Not Telling The Full Story
Those holding AxoGen, Inc. (NASDAQ:AXGN) shares would be relieved that the share price has rebounded 27% in the last thirty days, but it needs to keep going to repair the recent damage it has caused t
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn Into More Strength?
Axogen Processing Center (APC) Celebrates Its Opening With Ohio Leaders in Vandalia
ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft
AxoGen (AXGN) said Thursday it has started the rolling submission process for a biologics license application for Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograf
Express News | AxoGen Inc - Believe Procedural Timelines for Review Combined With Rolling Submission Process Will Allow for Approval Around Mid-2025
Express News | AxoGen Inc - Anticipate Bla Filing to Be Completed in Q3 of 2024
Express News | AxoGen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
ALACHUA, Fla. and TAMPA, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that